An emerging approach to overcome the constraints of MHC-restricted T cell receptor (TCR) activation, and lack of naturally occurring anti-tumor T cell responses, is to genetically modify a patient’s T cells to express chimeric antigen receptors (CARs) [16]. Here, HLA-C is linked to neoplasm.